Breast Cancer Awareness Ribbon
"There can be life after breast cancer. The prerequisite is early detection."
- Ann Jillian

BreastTrue® High Risk Panel

Genetic Testing for High Risk Incidences of Breast Cancer

What is BreastTrue® high risk panel?

BreastTrue® High Risk Panel is a next-generation sequencing test that detects mutations in eight high-risk breast cancer susceptibility genes, including BRCA1, BRCA2 and PALB2. In addition, the test includes deletion/duplication analysis of the BRCA1/2 genes by MLPA.

Recent studies of breast cancer survivors have shown that approximately 70 percent of the mutations identified were BRCA1/2 mutations. Approximately 4 percent had germline mutations in other cancer-susceptibility genes, including high-risk genes. These additional high-risk genes include CDH1, CHEK2, PALB2, PTEN, STK11, and TP53. Pathway Genomics’ BreastTrue® High Risk Panel analyzes all of these genes.

BreastTrue® High Risk Panel Resources

  1. Test Requisition Form
  2. Testing Summary
  3. Technical Bulletin
  4. White Paper

The Latest Research On PALB2

A new large study published in the New England Journal of Medicine shows that mutations in the PALB2 gene are important contributors to breast cancer risk. Read the abstract…

“Since the BRCA1 and BRCA2 mutations were discovered in the mid-90s, no other genes of similar importance have been found. PALB2 is a potential candidate to be BRCA3.”

Marc Tischkowitz, M.D., Ph.D.
Lead Study Author
Department of Medical Genetics
University of Cambridge

+ Testing Options

Below are the next-generation sequencing tests that Pathway Genomics offers for risk of hereditary breast cancer:

  1. BRCATrue®
  2. BreastTrue® High Risk Panel
  3. Single Site Testing

Reflex Options

  1. BRCATrue® with reflex to BreastTrue® High Risk Panel

+ High-Risk Hereditary Breast Cancers

Cancer Types Chart

+ Clinical Guidelines & Clinical Utility

High Risk Patient Criteria

The test is best suited for individuals with either a history of early onset breast or ovarian cancer or a strong family history of breast and/or ovarian cancer. Individuals with the following medical or family history factors should consider testing:

  • Early onset breast cancer (under 50 years of age)
  • Bilateral or multiple breast cancers
  • Diagnosed with both breast and ovarian cancer
  • Family history of breast and/or ovarian cancer
  • Male breast cancer within family
  • Ashkenazi Jewish ethnic background

Clinical Utility

  • Guide decisions on prevention strategies (e.g. chemoprevention, prophylactic surgery)
  • Increase surveillance for breast cancer
  • Inform treatment decisions
  • Identify family members at increased risk

+ References

  1. Petrucelli N, Daly MB, Feldman GL. BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2013 Sep 26]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1247/
  2. Smith, E.C., An overview of hereditary breast and ovarian cancer syndrome. J Midwifery Womens Health, 2012. 57(6): p. 577-84.
  3. Ford, D., et al., Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet, 1998. 62(3): p. 676-89.
  4. Antoniou, A., et al., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet, 2003. 72(5): p. 1117-30.
  5. Brose, M.S., et al., Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst, 2002. 94(18): p. 1365-72.
  6. Chen, S. and G. Parmigiani, Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol, 2007. 25(11): p. 1329-33.
  7. Mavaddat, N., et al., Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst, 2013. 105(11): p. 812-22.
  8. National_Cancer_Institute. SEER Cancer Statistics Review. [Website] 1975-2011 [cited 2015 January 13]; Available from: http://seer.cancer.gov/statfacts/.
  9. Dapic, V. and A.N. Monteiro, Functional implications of BRCA1 for early detection, prevention, and treatment of breast cancer. Crit Rev Eukaryot Gene Expr, 2006. 16(3): p. 233-52.
  10. Deng, C.X. and S.G. Brodie, Roles of BRCA1 and its interacting proteins. Bioessays, 2000. 22(8): p. 728-37.
  11. Huen, M.S., S.M. Sy, and J. Chen, BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol, 2010. 11(2): p. 138-48.
  12. Millot, G.A., et al., A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat, 2012. 33(11): p. 1526-37.
  13. Narod, S.A. and W.D. Foulkes, BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer, 2004. 4(9): p. 665-76.
  14. Roy, R., J. Chun, and S.N. Powell, BRCA1 and BRCA2: different roles in a common pathway of genome protection Nat Rev Cancer, 2012. 12(1): p. 68-78.
  15. Yun, M.H. and K. Hiom, Understanding the functions of BRCA1 in the DNA-damage response. Biochem Soc Trans, 2009. 37(Pt 3): p. 597-604.
  16. Kaurah P, Huntsman DG. Hereditary Diffuse Gastric Cancer. 2002 Nov 4 [Updated 2014 Jul 31]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1139/
  17. Guilford, P., B. Humar, and V. Blair, Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer, 2010. 13(1): p. 1-10.
  18. Schrader, K. and D. Huntsman, Hereditary diffuse gastric cancer. Cancer Treat Res, 2010. 155: p. 33-63.
  19. Corso, G., et al., Frequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: metanalysis and systematic review of the literature. BMC Cancer, 2012. 12: p. 8.
  20. Oliveira, C., et al., Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology, 2009. 136(7): p. 2137-48.
  21. Fitzgerald, R.C., et al., Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet, 2010. 47(7): p. 436-44.
  22. Seevaratnam, R., et al., A systematic review of the indications for genetic testing and prophylactic gastrectomy among patients with hereditary diffuse gastric cancer. Gastric Cancer, 2012. 15 Suppl 1: p. S153-63.
  23. Jones, S., et al., Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science, 2009. 324(5924): p. 217.
  24. Erkko, H., et al., A recurrent mutation in PALB2 in Finnish cancer families. Nature, 2007. 446(7133): p. 316-9.
  25. Poumpouridou, N. and C. Kroupis, Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges. Clin Chem Lab Med, 2012. 50(3): p. 423-34.
  26. Rahman, N., et al., PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet, 2007. 39(2): p. 165-7.
  27. Southey, M.C., Z.L. Teo, and I. Winship, PALB2 and breast cancer: ready for clinical translation! Appl Clin Genet, 2013. 6: p. 43-52.
  28. Evans, M.K. and D.L. Longo, PALB2 mutations and breast-cancer risk. N Engl J Med, 2014. 371(6): p. 566-8.
  29. Blumenthal, G.M. and P.A. Dennis, PTEN hamartoma tumor syndromes. Eur J Hum Genet, 2008. 16(11): p. 1289-300.
  30. Eng C. PTEN Hamartoma Tumor Syndrome (PHTS) 2001 Nov 29 [Updated 2014 Jan 23]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1488/
  31. Tan, M.H., et al., Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res, 2012. 18(2): p. 400-7.
  32. Hollander, M.C., G.M. Blumenthal, and P.A. Dennis, PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer, 2011. 11(4): p. 289-301.
  33. Salmena, L., A. Carracedo, and P.P. Pandolfi, Tenets of PTEN tumor suppression. Cell, 2008. 133(3): p. 403-14.
  34. Calva, D. and J.R. Howe, Hamartomatous polyposis syndromes. Surg Clin North Am, 2008. 88(4): p. 779-817, vii.
  35. McGarrity TJ, Amos CI, Frazier ML, et al. Peutz-Jeghers Syndrome. 2001 Feb 23 [Updated 2013 Jul 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1266/
  36. van Lier, M.G., et al., High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol, 2010. 105(6): p. 1258-64; author reply 1265.
  37. Hearle, N., et al., Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res, 2006. 12(10): p. 3209-15.
  38. Karuman, P., et al., The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell, 2001. 7(6): p. 1307-19.
  39. Marignani, P.A., LKB1, the multitasking tumour suppressor kinase. J Clin Pathol, 2005. 58(1): p. 15-9.
  40. Migliore, L., et al., Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol, 2011. 2011: p. 792362.
  41. Yajima, H., et al., Novel serine/threonine kinase 11 gene mutations in Peutz-Jeghers syndrome patients and endoscopic management. World J Gastrointest Endosc, 2013. 5(3): p. 102-10.
  42. Hwang, S.J., et al., Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet, 2003. 72(4): p. 975-83.
  43. Lustbader, E.D., et al., Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet, 1992. 51(2): p. 344-56.
  44. McBride, K.A., et al., Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol, 2014. 11(5): p. 260-71.
  45. Schneider K, Zelley K, Nichols KE, et al. Li-Fraumeni Syndrome. 1999 Jan 19 [Updated 2013 Apr 11]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1311/
  46. Chompret, A., et al., P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer, 2000. 82(12): p. 1932-7.
  47. Kamihara, J., H.Q. Rana, and J.E. Garber, Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat, 2014. 35(6): p. 654-62.
  48. Mai, P.L., et al., Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet, 2012. 205(10): p. 479-87.
  49. Ariffin, H., et al., Li-Fraumeni syndrome in a Malaysian kindred. Cancer Genet Cytogenet, 2008. 186(1): p. 49-53.
  50. Krypuy, M., et al., High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer, 2007. 7: p. 168.
  51. Malcikova, J., et al., Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation. Biol Chem, 2010. 391(2-3): p. 197-205.